Literature DB >> 14571256

The 5-HT(6) receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats.

Andrew G Foley1, Keith J Murphy, Warren D Hirst, Helen C Gallagher, Jim J Hagan, Neil Upton, Frank S Walsh, Ciaran M Regan.   

Abstract

The highly potent and selective 5-HT(6) receptor antagonist SB-271046 [5-chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide] has previously been demonstrated to improve retention significantly in a spatial water maze paradigm in adult rats. However, SB-271046 did not have any effect on task acquisition. As these apparently contradictory findings may be reconciled by a prime influence of SB-271046 on memory consolidation, the ability of this compound to reverse the discrete temporal action of a cholinergic antagonist in the 6-h period following passive avoidance training was investigated. SB-271046, given orally, by gavage, 30 min prior to training Wistar rats in a step-through, light-dark passive avoidance task, was found to reverse significantly the amnesia produced by administering scopolamine (0.8 mg/kg, intraperitoneal) in the 6-h post-training period. The effect was dose-dependent over a range of 3-20 mg/kg. Further, we investigated the cognition-enhancing effects of chronic SB-271046 administration (10 or 20 mg/kg/day; 40 days) on the acquisition and consolidation of a water maze spatial learning task in a population of 20-month-old Wistar rats with age-related learning deficits. Drug treatment progressively and significantly decreased platform swim angle and escape latencies over the five sequential trials on four consecutive daily sessions compared to vehicle-treated controls. SB-271046 also improved task recall as measured by significant increases in the searching of the target quadrant on post-training days 1 and 3, when the animals would have been substantially drug-free. This significant improvement of task recall suggests SB-271046, in addition to inducing symptomatic cognition-enhancing actions, also attenuates age-related decline in neural function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14571256     DOI: 10.1038/sj.npp.1300332

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  31 in total

Review 1.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

2.  Increased impulsivity and disrupted attention induced by repeated phencyclidine are not attenuated by chronic quetiapine treatment.

Authors:  Nurith Amitai; Athina Markou
Journal:  Pharmacol Biochem Behav       Date:  2008-09-08       Impact factor: 3.533

Review 3.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

4.  Increased expression of 5-HT₆ receptors in dorsolateral striatum decreases habitual lever pressing, but does not affect learning acquisition of simple operant tasks in rats.

Authors:  Daniel Eskenazi; John F Neumaier
Journal:  Eur J Neurosci       Date:  2011-06-30       Impact factor: 3.386

5.  5-HT6 receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice.

Authors:  Virginie Da Silva Costa-Aze; Anne Quiedeville; Michel Boulouard; François Dauphin
Journal:  Psychopharmacology (Berl)       Date:  2012-02-25       Impact factor: 4.530

6.  The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats.

Authors:  Eric G Mohler; Phillip M Baker; Kimberly S Gannon; Simon S Jones; Sharon Shacham; John A Sweeney; Michael E Ragozzino
Journal:  Psychopharmacology (Berl)       Date:  2011-10-12       Impact factor: 4.530

Review 7.  The role of serotonin in memory: interactions with neurotransmitters and downstream signaling.

Authors:  Mohammad Seyedabadi; Gohar Fakhfouri; Vahid Ramezani; Shahram Ejtemaei Mehr; Reza Rahimian
Journal:  Exp Brain Res       Date:  2014-01-16       Impact factor: 1.972

8.  Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat.

Authors:  B Marcos; T T Chuang; F J Gil-Bea; M J Ramirez
Journal:  Br J Pharmacol       Date:  2008-07-14       Impact factor: 8.739

Review 9.  5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease.

Authors:  Neil Upton; Tsu Tshen Chuang; Ann J Hunter; David J Virley
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

10.  Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex.

Authors:  Florence Loiseau; Anne Dekeyne; Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2007-10-06       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.